Peter Boros, Genetic Immunity’s President presented the Company’s pDNA-based platform technology and clinical trial data relating to HIV in front of an esteemed gathering of HIV experts. As part of the presentation, Genetic Immunity announced the launch of a Phase III clinical trial for the company’s lead product candidate, a therapeutic HIV vaccine, to be […]
Genetic Immunity Presents at First Russian-Chinese HIV Congress in Moscow
Leave a reply
